Open AccessPrimary gastrointestinal stromal tumor of the liver treated with sequential therapy
Author(s) -
Xianke Lin,
Qing Zhang,
Weili Yang,
Chunhui Shou,
Xiaosun Liu,
Jinhua Sun,
Jiren Yu
Publication year - 2015
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v21.i8.2573
Subject(s) - cd117 , imatinib mesylate , medicine , stromal tumor , sunitinib , gist , sunitinib malate , imatinib , cd34 , pathology , immunohistochemistry , hepatectomy , stromal cell , gastroenterology , cancer , surgery , biology , resection , genetics , stem cell , myeloid leukemia
A 67-year-old female presented with a primary hepatic gastrointestinal stromal tumor that was detected by computed tomography and diagnosed based on histopathological and genetic analyses. The tumor was microscopically composed of spindle cells and epithelioid cells, and immunohistochemistry results showed positive staining for CD117 and CD34 expression. A genetic analysis revealed a heterozygous point mutation and deletion in exon 11 of c-KIT. After an R0 resection, imatinib mesylate was administered for 1 year until its use was discontinued due to severe side effects. Two years after the original operation, the tumor recurred in the residual liver and was completely resected again. Imatinib mesylate was administered for 2 years until it was replaced by sunitinib malate because of disease progression. The patient has survived for 53 mo after undergoing a sequential therapy consisting of surgical excision, imatinib and sunitinib.